<DOC>
	<DOCNO>NCT00775502</DOCNO>
	<brief_summary>This study test ability specially design monoclonal antibody destroy multiple myeloma cell . This antibody unique ability promote death multiple myeloma cell process know antibody dependent cellular cytotoxicity ( ADCC ) complement dependent cytotoxicity ( CDC ) . The study design determine optimal dose antibody destroy multiple myeloma cell frequency dosing .</brief_summary>
	<brief_title>Phase 1/2 Study Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma</brief_title>
	<detailed_description>BIW-8962 monoclonal antibody target GM-2 ganglioside express high level surface multiple myeloma cell . This Phase 1/2 study design . The Phase 1 component establish active biologic dose ( ABD ) maximum tolerate dose ( MTD ) well appropriate dose frequency base pharmacokinetics antibody approximately 45 subject enrol part study . The initial dosing frequency every two week dose tested range 0.03 mg/kg 10 mg/kg . Once recommended Phase 2 dose frequency establish Phase 1 , efficacy drug investigate approximately 35 subject Phase 2 . The study proceed beyond Phase 1a portion . On 30 Nov 2010 , Kyowa Hakko Kirin Pharma , Inc. ( KKP ) notify Investigators decision terminate BIW-8962-001 due lack efficacy Multiple Myeloma . The Phase 1 Part B Phase 2 component study conduct . The study terminate summarize abbreviated clinical study report ( submit 26 June 2012 ; SN045 ) . Kyowa Kirin Pharma current plan pursue use BIW8962 multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed refractory myeloma Mprotein serum and/or urine IMWG criterion . Bone marrow plasma cell plasmacytoma Related organ tissue impairment ( CRAB ) Subjects without detectable M protein eligible abnormal serum free light chain ratio ( FLC ) least 10 % plasma cell bone marrow Ongoing infection Cardiac disease Uncontrolled hypertension Active liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>GM-2 ganglioside</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Potelligent design</keyword>
	<keyword>Treatment subject fail previous treatment</keyword>
</DOC>